200 related articles for article (PubMed ID: 38508140)
41. Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells.
Kuravi S; Cheng J; Fangman G; Polireddy K; McCormick S; Lin TL; Singh AK; Abhyankar S; Ganguly S; Welch DR; Jensen RA; McGuirk JP; Balusu R
Mol Cancer Res; 2021 May; 19(5):913-920. PubMed ID: 33514657
[TBL] [Abstract][Full Text] [Related]
42. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma.
Bard JD; Gelebart P; Anand M; Amin HM; Lai R
Leukemia; 2008 Aug; 22(8):1595-603. PubMed ID: 18509351
[TBL] [Abstract][Full Text] [Related]
43. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
44. De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.
Babin L; Darchen A; Robert E; Aid Z; Borry R; Soudais C; Piganeau M; De Cian A; Giovannangeli C; Bawa O; Rigaud C; Scoazec JY; Couronné L; Veleanu L; Cieslak A; Asnafi V; Sibon D; Lamant L; Meggetto F; Mercher T; Brunet E
Mol Cancer; 2022 Mar; 21(1):65. PubMed ID: 35246138
[TBL] [Abstract][Full Text] [Related]
45. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.
Pearson JD; Lee JK; Bacani JT; Lai R; Ingham RJ
Int J Clin Exp Pathol; 2011 Jan; 4(2):124-33. PubMed ID: 21326808
[TBL] [Abstract][Full Text] [Related]
46. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.
Weilemann A; Grau M; Erdmann T; Merkel O; Sobhiafshar U; Anagnostopoulos I; Hummel M; Siegert A; Hayford C; Madle H; Wollert-Wulf B; Fichtner I; Dörken B; Dirnhofer S; Mathas S; Janz M; Emre NC; Rosenwald A; Ott G; Lenz P; Tzankov A; Lenz G
Blood; 2015 Jan; 125(1):124-32. PubMed ID: 25359993
[TBL] [Abstract][Full Text] [Related]
47. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
Shi P; Lai R; Lin Q; Iqbal AS; Young LC; Kwak LW; Ford RJ; Amin HM
Blood; 2009 Jul; 114(2):360-70. PubMed ID: 19423729
[TBL] [Abstract][Full Text] [Related]
48. Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/β-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma.
Wu C; Gupta N; Huang YH; Zhang HF; Alshareef A; Chow A; Lai R
BMC Cancer; 2018 Apr; 18(1):361. PubMed ID: 29609590
[TBL] [Abstract][Full Text] [Related]
49. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.
Zamo A; Chiarle R; Piva R; Howes J; Fan Y; Chilosi M; Levy DE; Inghirami G
Oncogene; 2002 Feb; 21(7):1038-47. PubMed ID: 11850821
[TBL] [Abstract][Full Text] [Related]
50. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.
Ambrogio C; Martinengo C; Voena C; Tondat F; Riera L; di Celle PF; Inghirami G; Chiarle R
Cancer Res; 2009 Nov; 69(22):8611-9. PubMed ID: 19887607
[TBL] [Abstract][Full Text] [Related]
51. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
Merkel O; Hamacher F; Laimer D; Sifft E; Trajanoski Z; Scheideler M; Egger G; Hassler MR; Thallinger C; Schmatz A; Turner SD; Greil R; Kenner L
Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16228-33. PubMed ID: 20805506
[TBL] [Abstract][Full Text] [Related]
52. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma.
Kutok JL; Aster JC
J Clin Oncol; 2002 Sep; 20(17):3691-702. PubMed ID: 12202671
[TBL] [Abstract][Full Text] [Related]
53. IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas.
Bandini C; Pupuleku A; Spaccarotella E; Pellegrino E; Wang R; Vitale N; Duval C; Cantarella D; Rinaldi A; Provero P; Di Cunto F; Medico E; Bertoni F; Inghirami G; Piva R
Cancers (Basel); 2018 Jan; 10(1):. PubMed ID: 29346274
[TBL] [Abstract][Full Text] [Related]
54. Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma.
Wang X; Wu J; Zhang M
Hematology; 2019 Dec; 24(1):440-445. PubMed ID: 31072226
[TBL] [Abstract][Full Text] [Related]
55. Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma.
Hamedani FS; Cinar M; Mo Z; Cervania MA; Amin HM; Alkan S
Leuk Res; 2014 Apr; 38(4):503-8. PubMed ID: 24486291
[TBL] [Abstract][Full Text] [Related]
56. Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma.
Tabbò F; Ponzoni M; Rabadan R; Bertoni F; Inghirami G;
Curr Opin Hematol; 2013 Jul; 20(4):374-81. PubMed ID: 23673339
[TBL] [Abstract][Full Text] [Related]
57. Identification of C/EBPβ target genes in ALK+ anaplastic large cell lymphoma (ALCL) by gene expression profiling and chromatin immunoprecipitation.
Bonzheim I; Irmler M; Klier-Richter M; Steinhilber J; Anastasov N; Schäfer S; Adam P; Beckers J; Raffeld M; Fend F; Quintanilla-Martinez L
PLoS One; 2013; 8(5):e64544. PubMed ID: 23741337
[TBL] [Abstract][Full Text] [Related]
58. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma.
Singh RR; Cho-Vega JH; Davuluri Y; Ma S; Kasbidi F; Milito C; Lennon PA; Drakos E; Medeiros LJ; Luthra R; Vega F
Cancer Res; 2009 Mar; 69(6):2550-8. PubMed ID: 19244133
[TBL] [Abstract][Full Text] [Related]
59. C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway.
Anastasov N; Bonzheim I; Rudelius M; Klier M; Dau T; Angermeier D; Duyster J; Pittaluga S; Fend F; Raffeld M; Quintanilla-Martinez L
Haematologica; 2010 May; 95(5):760-7. PubMed ID: 20015877
[TBL] [Abstract][Full Text] [Related]
60. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.
Laurent C; Delas A; Gaulard P; Haioun C; Moreau A; Xerri L; Traverse-Glehen A; Rousset T; Quintin-Roue I; Petrella T; Emile JF; Amara N; Rochaix P; Chenard-Neu MP; Tasei AM; Menet E; Chomarat H; Costes V; Andrac-Meyer L; Michiels JF; Chassagne-Clement C; de Leval L; Brousset P; Delsol G; Lamant L
Ann Oncol; 2016 Feb; 27(2):306-14. PubMed ID: 26598546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
